Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock that Sean E. Brynjelsen plans to sell under Rule 144. The notice lists a proposed sale of 100,000 common shares through Raymond James & Associates and discloses that 120,000 shares of common stock were sold on 05/28/2026 for about $3,826,015.00. The securities to be sold trace back to 1,000,000 founder shares acquired on 05/17/2017.
Eton Pharmaceuticals, Inc. (ETON) is the issuer of common stock for which Sean E. Brynjelsen has filed a notice to sell shares under Rule 144. The notice covers 100,000 shares of common stock to be sold through Raymond James & Associates, Inc., with an aggregate market value of $6,343,000.00 and 28,583,135 shares of this class outstanding as of the notice. The shares are described as Founder Shares acquired from the issuer on 05/17/2017 by grant, and are listed on Nasdaq. No shares are reported as sold during the past three months.
Eton Pharmaceuticals, Inc. reported strong growth for the quarter and six months ended June 30, 2026. Quarterly net revenues were $37,589 (thousands), up from $18,928, driven mainly by higher sales of INCRELEX®, GALZIN®, Carglumic Acid and the addition of HEMANGEOL®.
Gross profit for the quarter rose to $25,413 from $11,924, and Eton moved from a net loss of $(2,585) to net income of $11,578. For the first half of 2026, revenues increased to $61,855 from $36,210, with net income of $13,132 versus a loss of $(4,157) a year earlier. Adjusted EBITDA for the six months improved to $21,944 from $6,726.
The company ended June 30, 2026 with $26,845 in cash and cash equivalents, total assets of $115,807, and working capital of $23,500 (thousands). It invested $14,000 to acquire U.S. commercial rights to HEMANGEOL® and $1,000 for an ultra-rare disease product candidate, and expanded its rare disease portfolio while carrying $27,903 of net debt under its SWK credit facility. Revenues and receivables remain highly concentrated with specialty pharmacy customer AnovoRx.
Eton Pharmaceuticals reported very strong results for the quarter ended June 30, 2026. Net revenue was $37.6 million, up 99% from $18.9 million a year earlier, driven by the HEMANGEOL relaunch and growth across the rare disease portfolio, including INCRELEX, ALKINDI SPRINKLE, GALZIN and Carglumic Acid. Gross profit rose to $25.4 million, while adjusted gross profit reached $27.4 million with a 73% margin.
Operating leverage improved markedly: EBITDA was $14.1 million versus a small loss a year ago, and Adjusted EBITDA was $16.2 million, or 43% of revenue. GAAP net income was $11.6 million (diluted EPS $0.35), compared with a $2.6 million loss (−$0.10 per share) in the prior-year quarter; non-GAAP net income was $14.3 million (diluted EPS $0.43). Cash and equivalents were $26.8 million at quarter end.
The company raised 2026 guidance and now expects revenue above $145 million and an Adjusted EBITDA margin of at least 35%, both higher than prior targets. Management highlighted successful HEMANGEOL patient transition, the ASN-001 licensing, the planned AMGLIDIA NDA by end-2026, the IMPAVIDO launch expected in September 2026, and multiple ongoing label and development studies across its rare disease pipeline.
Eton Pharmaceuticals’ Chief Operating Officer Danka Radosavljevic filed an initial statement of beneficial ownership, detailing equity interests in Eton common stock and equity awards. Reported positions include multiple employee stock options with exercise prices ranging from $1.38 to $15.47 per share and expiration dates between 2027 and 2036, time-vested restricted stock units, and a sizeable performance-based award.
The performance-vested restricted stock unit grant covers 128,985 potential shares and vests in full only if Eton’s common stock closing price reaches or exceeds $72.36 for one trading day on or before July 31, 2029; otherwise, it is forfeited. The filing reflects holdings only and does not report any concurrent purchases or sales.
Eton Pharmaceuticals entered into a material license agreement with Auson Pharmaceuticals for U.S. rights to ASN-001, a late-stage timolol topical gel for proliferating superficial infantile hemangiomas. Eton will pay an upfront license fee of $3.0 million within thirty days and will run a bioavailability bridging study, with plans to submit a New Drug Application in the second half of 2027.
Following FDA approval of ASN-001, Auson is eligible for a $5,000,000 milestone when annual net sales reach $80,000,000 and $10,000,000 when they reach $150,000,000, plus tiered royalties of 10%, 13% and 15% on cumulative lifetime net product sales across specified net sales tiers. A three‑arm Phase II/III trial in 168 patients showed elimination or near-elimination of infantile hemangiomas at week 24 in 56% of twice-daily and 42% of three-times-daily ASN-001 patients, versus 15% with placebo.
Eton positions ASN-001 as a topical therapy complementary to its systemic product HEMANGEOL, targeting an estimated 20,000 to 30,000 U.S. patients within a broader pool of more than 100,000 affected infants annually. If approved, ASN-001 is expected to be the first FDA-approved topical therapy for infantile hemangiomas and benefits from patent protection through 2044.
CASAMENTO CHARLES J reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals director Charles J. Casamento received a grant of 10,000 performance-vested restricted stock units, each representing one share of common stock. The award vests in full only if the share price reaches $72.36 or higher for one trading day before July 31, 2029, otherwise it is forfeited.
Eton Pharmaceuticals, Inc. reported that Chief Financial Officer Judith M. Matthews received a grant of 32,246 performance-vested restricted stock units under the company's 2018 equity incentive plan. Each unit represents the right to acquire one share of common stock.
The award vests in full only if the closing price of Eton's common stock equals or exceeds $72.36 per share for one trading day at any time before July 31, 2029; if this market condition is not satisfied, the entire award is forfeited without consideration. The filing characterizes the transaction as a grant or award acquisition rather than an open-market purchase.
Erdogan-Trinkaus Ipek reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals granted Chief Commercial Officer Ipek Erdogan-Trinkaus 80,000 performance-vested restricted stock units on July 31, 2026 under its 2018 equity incentive plan. Each unit entitles the holder to one common share if the stock’s closing price reaches $72.36 or higher for one trading day within three years; otherwise the entire award, the only 80,000 shares issuable, is forfeited on July 31, 2029.
BRYNJELSEN SEAN reported acquisition or exercise transactions in this Form 4 filing.
Eton Pharmaceuticals, Inc. granted President & CEO Sean Brynjelsen 128,985 performance-vested restricted stock units under its 2018 equity incentive plan on July 31, 2026.
Each unit represents one common share and vests only if the stock’s closing price reaches at least $72.36 for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without payment on July 31, 2029.